Retraction of: Scientific Reports https://doi.org/10.1038/srep39905, published online 04 January 2017
The Authors are retracting this Article.
During the preparation of the figures the Authors included previously published microscopy and Western blotting data in Figures 1, 2, 3, and 7. Additionally, the authors are unable to locate the correct original data for the Western blot experiments and therefore cannot guarantee the accuracy of the data presented in Figures 2, 3, and 7, which is key to the conclusions of this Article.
All authors agree to the retraction.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Luo, J., Liu, Yh., Luo, W. et al. Retraction Note: β2-adrenoreceptor Inverse Agonist Down-regulates Muscarine Cholinergic Subtype-3 Receptor and Its Downstream Signal Pathways in Airway Smooth Muscle Cells in vitro. Sci Rep 9, 4109 (2019). https://doi.org/10.1038/s41598-019-39065-w
Published:
DOI: https://doi.org/10.1038/s41598-019-39065-w
This article is cited by
-
Clinical Efficacy of Long-Acting β2 Agonists and Long-Acting Muscarinic Antagonist for Moderate to Severe Chronic Obstructive Pulmonary Disease
Pharmaceutical Chemistry Journal (2023)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
